Medical device manufacturing: design controls decide when you are allowed to sell

Risk class chooses the route, and the route sets the calendar

Where a device sits on the risk scale determines whether market access is a matter of demonstrating equivalence to something already available, or of assembling clinical evidence and submitting to a conformity assessment by a designated body. Those two paths differ by a wide margin in cost and elapsed time, and the classification is not always obvious for novel products. Founders routinely build a financial plan around the faster route and discover late that their intended use statement pushed them onto the slower one. Getting the classification and intended use settled early, with regulatory advice, changes the funding requirement more than any engineering decision does.

Design controls freeze the product earlier than engineers expect

The quality system requires that requirements, design outputs, verification, validation and risk management form a traceable record, with the design formally transferred to manufacturing. In practice this means the moment of design freeze arrives while engineers still have improvements they want to make. Changes after freeze are not forbidden but they are expensive, because each one ripples through verification evidence, risk files and possibly regulatory submissions. Teams that treat documentation as something to catch up on after the prototype works end up rebuilding the record retrospectively, which auditors detect easily and which delays launch far more than doing it properly would have.

The factory is validated, not merely equipped

Buying the equipment is the small part. Installation, operational and performance qualification must demonstrate that the process consistently produces conforming product, cleanrooms must be qualified and monitored continuously, and operators must be trained and their training recorded. Sterilisation is usually contracted out, which places a critical process under someone else's capacity constraints and someone else's regulatory scrutiny. Moving a validated process to a different machine, a different room or a different site is a project measured in months, which is why device manufacturing footprints change slowly even when commercial logic argues for relocation.

Supplier change control makes switching genuinely expensive

Component suppliers cannot be swapped on price. A change of resin grade, adhesive, sensor or contract steriliser has to be assessed, potentially verified and sometimes notified, and the assessment must be documented before the change is implemented rather than after. Suppliers who discontinue a material without notice create a serious problem, so device makers write change notification obligations into supply agreements and treat that clause as more important than the price. This is also why device companies tolerate supplier prices that a general manufacturer would refuse: the qualified alternative may not exist.

Hospitals buy on evidence, tender and a clinical advocate

Selling a device involves at least three decisions inside a customer: a clinician who wants it, a procurement function running a formal process against price and contract terms, and often a committee assessing evidence and budget impact. A product with no clinical champion does not get onto a tender list; a product with a champion but no health economic argument gets blocked at the committee. Group purchasing arrangements add another layer, since a supplier outside the agreement may be effectively unable to sell regardless of merit. Time from regulatory clearance to first meaningful revenue is usually dominated by this, not by the regulator.

Frequently asked questions

Why does relocating device production take so long?

Because the process, not just the equipment, carries the approval. A new site requires facility qualification, requalification of processes on the installed equipment, environmental monitoring history, retrained and requalified operators, and updated documentation, followed in many cases by notification to regulators and by customer or notified body assessment. Running the old and new sites in parallel during the transition doubles cost temporarily. Companies that plan a move as an equipment logistics exercise consistently underestimate it.

What does a single supplier change actually trigger?

An assessment of whether the change affects device safety or performance, which may require verification testing, updates to the risk file and the design history record, and a decision on whether the change is significant enough to require notification to a regulator or notified body. Where the component is in contact with the patient or affects sterility, biocompatibility or packaging validation may need revisiting. The practical effect is that supplier changes are planned quarters ahead rather than made opportunistically.

Why do device start-ups underestimate the cost of their second product?

Because the first product's approval and quality system feel like fixed costs that will now be spread. In reality each new device brings its own risk management, verification, clinical evidence and post-market obligations, and it expands the quality organisation rather than reusing spare capacity. Manufacturing may share a cleanroom but rarely shares validated processes. Companies that assumed platform economics often find the second launch costs a substantial fraction of the first.